Table 7 Change in HbA1c with DPP-4i use, N = 105
From: Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
Pre DPP-4i use | Post DPP-4i use | Mean difference ± 95% CI | P value£ | P value¥ | |
|---|---|---|---|---|---|
Age (years old) | |||||
< 60 | 8.7 ± 2.0 | 7.8 ± 1.7 | 0.89 (0.44,1.34) | < 0.0001* | 0.963 |
≥ 60 | 8.3 ± 1.5 | 7.4 ± 1.6 | 0.91 (0.45,1.36) | < 0.0001* | |
Type of DPP-4i | |||||
Vildagliptin | 8.1 ± 1.5 | 7.4 ± 1.6 | 0.68 (0.21, 1.14) | 0.006* | 0.011¢ |
Sitagliptin | 9.2 ± 2.2 | 7.5 ± 1.8 | 1.66 (0.95, 2.37) | < 0.0001* | |
Saxagliptin | 8.4 ± 1.4 | 8.0 ± 1.5 | 0.33 (−0.03, 0.67) | 0.052 | |
Linagliptin | 8.8 ± 2.1 | 8.1 ± 2.1 | 0.76(−1.12, 2.64) | 0.370 | |
Gender | |||||
Male | 8.5 ± 1.8 | 7.4 ± 1.5 | 1.13 (0.59, 1.66) | < 0.0001* | 0.162 |
Female | 8.6 ± 1.8 | 7.9 ± 1.8 | 0.68 (0.31, 1.04) | < 0.0001* | |
Therapy | |||||
FDC | 8.6 ± 1.8 | 7.6 ± 1.7 | 0.99 (0.60, 1.38) | < 0.0001* | 0.455 |
Single pill | 8.5 ± 1.8 | 7.8 ± 1.7 | 0.74 (0.18, 1.30) | 0.011* | |
Insulin | |||||
Yes | 9.0 ± 2.0 | 8.2 ± 1.9 | 0.81 (0.37, 1.25) | < 0.0001* | 0.554 |
No | 8.0 ± 1.5 | 7.0 ± 1.1 | 1.00 (0.53, 1.48) | < 0.0001* | |
Sulphonylurea | |||||
Yes | 8.2 ± 1.1 | 7.2 ± 1.1 | 0.96 (0.36, 1.56) | 0.003* | 0.824 |
No | 8.7 ± 2.0 | 7.8 ± 1.8 | 0.88 (0.49, 1.26) | < 0.0001* | |